Anlotinib combined with pemetrexed as a further treatment of patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study
Publication
, Conference
Chen, J; Wei, W; Zheng, L; Li, H; Feng, Y; Wan, T; Qiu, J; Jiang, X; Xiong, Y; Li, J; Huang, H; Song, L; Liu, J; Zhang, Y
Published in: Gynecologic Oncology
August 2021
Duke Scholars
Published In
Gynecologic Oncology
DOI
ISSN
0090-8258
Publication Date
August 2021
Volume
162
Start / End Page
S61 / S62
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Chen, J., Wei, W., Zheng, L., Li, H., Feng, Y., Wan, T., … Zhang, Y. (2021). Anlotinib combined with pemetrexed as a further treatment of patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study. In Gynecologic Oncology (Vol. 162, pp. S61–S62). Elsevier BV. https://doi.org/10.1016/s0090-8258(21)00758-7
Chen, Jueming, Wei Wei, Lie Zheng, Han Li, Yanling Feng, Ting Wan, Jiaqi Qiu, et al. “Anlotinib combined with pemetrexed as a further treatment of patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study.” In Gynecologic Oncology, 162:S61–62. Elsevier BV, 2021. https://doi.org/10.1016/s0090-8258(21)00758-7.
Chen J, Wei W, Zheng L, Li H, Feng Y, Wan T, et al. Anlotinib combined with pemetrexed as a further treatment of patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study. In: Gynecologic Oncology. Elsevier BV; 2021. p. S61–2.
Chen, Jueming, et al. “Anlotinib combined with pemetrexed as a further treatment of patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study.” Gynecologic Oncology, vol. 162, Elsevier BV, 2021, pp. S61–62. Crossref, doi:10.1016/s0090-8258(21)00758-7.
Chen J, Wei W, Zheng L, Li H, Feng Y, Wan T, Qiu J, Jiang X, Xiong Y, Li J, Huang H, Song L, Liu J, Zhang Y. Anlotinib combined with pemetrexed as a further treatment of patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study. Gynecologic Oncology. Elsevier BV; 2021. p. S61–S62.
Published In
Gynecologic Oncology
DOI
ISSN
0090-8258
Publication Date
August 2021
Volume
162
Start / End Page
S61 / S62
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis